Therapy-related myeloid neoplasms: Clinical perspectives

Luana Fianchi, Marianna Criscuolo, Emiliano Fabiani, Giulia Falconi, Alessio Maria Edoardo Maraglino, Maria Teresa Voso, Livio Pagano

Research output: Contribution to journalReview articlepeer-review


Therapy-related myeloid neoplasms (t-MNs) are a complication of cytotoxic treatment for primary tumors and autoimmune diseases. t-MNs result from a complex interaction between individual predisposition and exposition to toxic agents. Some different biological and clinical characteristics can be recognized according to the type of anticancer drug. Compared to de novo myeloid neoplasms, prognosis of t-MN is dismal. Age and karyotype are the most important prognostic factors for t-MN, which should be treated with frontline chemotherapy treatments that are appropriate for patients with myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) with similar disease characteristics. Allogeneic stem cell transplantation should be considered particularly for unfavorable karyotypes and younger patients with aggressive disease.

Original languageEnglish
Pages (from-to)5909-5915
Number of pages7
JournalOncoTargets and Therapy
Publication statusPublished - Jan 1 2018


  • Leukemia
  • Prognosis
  • Secondary leukemia
  • Secondary myelodysplastic syndrome
  • Therapy-related myeloid neoplasm

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Therapy-related myeloid neoplasms: Clinical perspectives'. Together they form a unique fingerprint.

Cite this